Programme ⇽ BioTrinity 2023 | OBN (UK) Ltd‌ on Glue Up

Tuesday, April 25, 2023 8:00^AM to 5:15^PM

9:00^AM - 10:30^AM

R&D Spotlight: Oncology
David Blakey•Alfie Brennan•Stuart Farrow•Peter Llewellyn-Davies•Jim Millen•Moritz Haneklaus

Kindly sponsored by Precision for Medicine

David Blakey
CSO at FasT Biopharma
Alfie Brennan
Principal Scientist at Evariste
Stuart Farrow
Vice President of Biosciences at Cancer Research Horizons
Peter Llewellyn-Davies
CEO of invIOs GmbH
Jim Millen
Director of Kargenera
Moritz Haneklaus
Senior Scientist at Macomics Limited

10:30^AM - 12:00^PM

R&D Spotlight: Vaccines, Infectious Diseases & Microbiome
Richard Bungay•Jeremy Skillington•Kirsty Smitten•Douglas Thomson•David Browning•Nik Sharma

Richard Bungay
CEO of Imophoron Ltd
Jeremy Skillington
CEO of Poolbeg Pharma PLC
Kirsty Smitten
CEO of MetalloBio
Douglas Thomson
CEO of Pneumagen Ltd
David Browning
CEO of Fixed Phage
Nik Sharma
Co-Founder CEO of BioCorteX

12:00^PM - 1:00^PM

Lunch & Networking

1:00^PM - 1:40^PM

Technical Update: Quantum Computing & Life Sciences
David Grimm•Sonali Mohapatra

This session will feature a 15 minute presentation from Sonali Mohapatra, Quantum Innovation Sector Lead at the National Quantum Computing Centre (NQCC) on the potential impact that Quantum Computing will have on drug discovery. Followed by an investment update from David Grimm, Investment Director at Albion VC. David manages the UCL Technology Fund’s Computer and Physical Sciences investment team. Investing in a wide range of exciting deeptech opportunities, including Quantum Computing, Machine Learning and Data Analytics, Cleantech, Medtech, Edtech and Hardware.

There will be the opportunity for audience Q&A after the presentations.

David Grimm
Investment Director of UCL Technology Fund
Sonali Mohapatra
Quantum Innovation Sector Lead at National Quantum Computing Centre

1:40^PM - 2:30^PM

R&D Spotlight: Platforms
Robert Grundy•Aneesh Karatt Vellatt•Michael Roberts•Daniel Ives

Robert Grundy
Vice President, Business Development at Intelligent OMICS
Aneesh Karatt Vellatt
CSO and Co-founder of Maxion Therapeutics
Michael Roberts
CEO of Chromatin Bioscience
Daniel Ives
CEO and Founder of Shift Bioscience

2:30^PM - 4:00^PM

R&D Spotlight: Medtech
Alex Batchelor•Alex Charitou•George Frodsham•Victor Harabari•Antoine Pouppez•Nick Skaer•Mikesh Udani

Alex Batchelor
CEO of Pictura Bio Ltd
Alex Charitou
Partner | Life Sciences at EY
George Frodsham
CEO of MediSieve Limited
Victor Harabari
Founder and CEO of Cardiocrown
Antoine Pouppez
CEO of NeuroClues
Nick Skaer
CEO of Orthox Limited
Mikesh Udani
CEO of Albus Health

4:00^PM - 5:15^PM

R&D Spotlight: Rare Diseases
Rebecca Abram•Lisa Conte•Anna Perdrix Rosell•Jonathan Rees•Dan Williams

Kindly sponsored by FUJIFILM Diosynth Biotechnologies

Rebecca Abram
Director, Strategic Technical Marketing of Fujifilm Diosynth Biotechnologies
Lisa Conte
President/CEO Jaguar Health and Chairman, BOD, Napo Therapeutics of Jaguar Health Inc.
Anna Perdrix Rosell
co-CEO and co-founder of Sixfold Bioscience
Jonathan Rees
CEO of MitoRx Therapeutics Limited
Dan Williams
CEO of SynaptixBio

Wednesday, April 26, 2023 8:00^AM to 4:00^PM

9:15^AM - 10:30^AM

R&D Spotlight: Neuroscience
Jenny Barnett•Christophe Gaudin•Peter Hamley•Jerome Parcq•James Peach•Simon Loiodice

Jenny Barnett
CEO of Monument Therapeutics Limited
Christophe Gaudin
CEO of Op2lysis
Peter Hamley
Chief Scientific Officer at Samsara Therapeutics Ltd
Jerome Parcq
Co-Founder of Op2lysis
James Peach
CEO of Human Centric DD Ltd
Simon Loiodice
Co-Founder and CEO of Karla Tx

10:30^AM - 11:45^AM

R&D Spotlight: Oncology
Francesca Rapino•Graeme Rogers•Alan Roth•Szabolcs Nagy•Clare Wareing•Igor Matushansky

Kindly sponsored by Ipsen

Francesca Rapino
COO at Theratrame
Graeme Rogers
Chief Scientific Officer at Omideon
Alan Roth
CEO of Oxford Drug Design
Szabolcs Nagy
Founder, CEO of Turbine AI
Clare Wareing
Founder & Chief Executive Officer of Cumulus Oncology
IM
Igor Matushansky
Global Head, Oncology Therapeutic Area at Ipsen

11:45^AM - 12:15^PM

Technical Update: Targeted Protein Degradation • Progress, Direction and Prospects
Sheelagh Frame

Sheelagh Frame
CSO at Ubiquigent LtdMore information about speaker

12:30^PM - 1:30^PM

Lunch & Networking

1:30^PM - 2:45^PM

R&D Spotlight: Inflammatory Disease
Salman Rahman•Jason Rutt•Kirsty Semple•Mark Peakman•Mark Dowling

Kindly sponsored by Sanofi

Salman Rahman
CEO of Vasgen Ltd
Jason Rutt
Founder and CEO of Azadyne
Kirsty Semple
CEO of SENISCA Ltd
Mark Peakman
Head of Autoimmunity Cluster, Immunology & Inflammation Research at Sanofi
Mark Dowling
Head External Innovation Immunology at Sanofi

2:45^PM - 4:00^PM

R&D Spotlight: Cell & Gene Therapy
James Barwick-Silk•Simon Chandler•Carin Ingemarsdotter•Carolyn Porter•Vlad Seitan•Sapan Gandhi

Kindly sponsored by Syneos Health

James Barwick-Silk
Director, Scientific Strategy, Cell & Gene Therapy of Syneos Health
Simon Chandler
CEO of Rinri Therapeutics Ltd.
Carin Ingemarsdotter
Co-Founder and COO of Spliceor Therapeutics
Carolyn Porter
CEO of CytoSeek
Vlad Seitan
CSO at Laverock Therapeutics
Sapan Gandhi
Founder of Drishti Discoveries

Tuesday, April 25, 2023 8:00^AM to 4:30^PM

8:45^AM - 9:00^AM

OBN CEO Welcome to BioTrinity
Stuart Rose

Stuart Rose
CEO of OBN (UK) LtdMore information about speaker

9:00^AM - 9:30^AM

Keynote: Investment Trends for the Life Sciences Industry
Tim Haines

Businesses across the UK have been battling against a backdrop of global economic uncertainty, exacerbated by soaring inflation, the cost-of-living crisis and rising costs over the past year. Whilst it’s been a challenging time across the board, the life sciences industry has continued to show resilience.
This session will take a deep dive into what the future looks like for life sciences and predictions for 2023 and beyond.

Tim Haines
Managing Partner at Abingworth

9:30^AM - 10:30^AM

Panel: Interesting Investment Case Studies
Leigh Brody•Clare Terlouw•Neil Torbett•Oliver Sexton•Emma Palmer Foster

The future growth of the life sciences sector and the achievement of ‘science superpower’ status will only be realised alongside an evolving, competitive fundraising environment and ever increasing deal activity for both seed and Series A funding that supports early stage innovation.
This session will spotlight some of the latest and most interesting investment deals, looking at successes and challenges and identifying where there needs to be change in the future to ensure the right funding is available to the right companies at the right time.
Our panel of industry leaders will provide a broad update on academic investments, charity collaborations, specialist seed funding as well as the perspective of an R&D company leader and identify what’s working and what needs improvement.

Leigh Brody
Investment Manager at UCL Technology Fund
Clare Terlouw
Head of LifeArc Ventures at LifeArc Ventures
Neil Torbett
CEO of PhoreMost
Oliver Sexton
Investment Director of UKi2S
Emma Palmer Foster
CONSULTANT at EJ Palmer Consulting

10:30^AM - 11:15^AM

Keynote: An Update on the New Regulatory Environment
Keith McDonald•Carole Pugh•Kathy Hills

This session will provide insight on the major developments in UK policy and regulation in life sciences – to include areas such as tax, use of data, clinical trial testing of medicines, and the use of artificial intelligence tools and medical devices.

Keith McDonald
Senior Director, Global Regulatory Affairs of IQVIA
Carole Pugh
General Manager at QbD
Kathy Hills
Partner Corporate Tax at Penningtons Manches Cooper

11:15^AM - 12:00^PM

Update: UK Government Life Sciences Strategy

12:00^PM - 1:00^PM

Lunch & Networking

1:00^PM - 2:00^PM

Panel: Exciting Exits • An insight into the latest collaboration, acquisitions, co-development success stories
Julie Gilmore•Michael Kyriakides•David Llewellyn•James Tumbridge•Anand Ashok

During this session, our broad mix of speakers will share their thoughts and personal experiences of the latest exit trends for UK life science companies, including:
• How Big Pharma is fuelling M&A activity
• Strategic collaboration success stories
• An update on IPOs
• Long term investor commitment

Julie Gilmore
Vice President and Global Head Lilly Gateway Labs at Lilly
Michael Kyriakides
Partner at Syncona
David Llewellyn
CEO & Co-Founder of DJS Antibodies
James Tumbridge
Barrister, Partner at Venner Shipley LLP at Venner Shipley Intellectual Property
Anand Ashok
Corporate Finance Associate Director of BDO

2:00^PM - 3:00^PM

Panel: Building a Sustainable Business • Green Science & ESG
Jim Bratherton•Chris Kimber-Nickelson•Kath Mackay•Nils Rage•Panteli Theocharous•Uma Sagaram

Kindly sponsored by Thermo Fisher Scientific

This session will address the impact that scientific innovation has on the environment, and what companies can do (and are already doing) to significantly reduce the environmental footprint of their scientific research.
This panel comprises experts from all corners of the industry, from lab users, lab providers, science parks and green science innovators, who are all on a combined mission to create a culture of sustainability in science, and show that it is possible to create life-changing innovations whilst limiting the environmental impact.

Jim Bratherton
Green Solutions Program Manager at Fisher Scientific UK
Chris Kimber-Nickelson
Development Director of MEPC
Kath Mackay
Director of Life Sciences at Bruntwood SciTech
Nils Rage
Head of Environment, Social and Governance (ESG) at Stanhope - Oxford North
Panteli Theocharous
Global Vice President, Cell and Gene Therapy Strategy Lead at PPD, part of Thermo Fisher Scientific
Uma Sagaram
CSO at CyanoCapture

3:00^PM - 4:30^PM

Innovate UK Hosted session

Wednesday, April 26, 2023 8:00^AM to 3:30^PM

10:00^AM - 11:00^AM

Panel: The CEO of the Future
Jack O'Meara•Malcolm Silander•Kirsty Smitten•Emma Tinsley

This session features an outstanding group of CEOs who have proven themselves to be ahead of the curve during these transformative times for the life sciences industry.
During the session we’ll hear about the major changes seen in the external environment that’s impacted business operations over recent years e.g. Driving productivity through the adoption of new processes, the need for speed and simplification, driving digitisation, being open to new and varied collaboration and ensuring patient centricity remains at the heart of everything.
We’ll also dig into to how each CEO has successfully inspired and led their teams during the period of ‘Great Re-imagination’ post Covid – and look at their expectations for continued change and evolution in the future.

Jack O'Meara
CEO of Ochre Bio
Malcolm Silander
Founder of Precision BioSearch
Kirsty Smitten
CEO of MetalloBio
Emma Tinsley
CEO of Weatherden

11:00^AM - 12:00^PM

Panel, Q&A: Big Pharma Showcase
Laia Crespo•Jan-Philipp Kruse•Laura Lane•Andrew McConaghie•Alistair Henry

Kindly sponsored by Citeline

Session Overview - During this session our moderator will invite feedback from four Big Pharma major players on a range of topics including:
• What are the new technologies and emerging trends that you are most excited about and believe will be most disruptive to both the pharma industry and patients in the coming years?
• With an ongoing societal shift to focus on prevention rather than cure, how are Big Pharma incorporating this into their long term development strategies and reimagined business models?
• How important is collaboration between big pharma, innovative R&D companies, investors, charities, and Government when tackling disease cures and treatments? Has this model of collaboration changed in recent years and what are the predictions for future relationships?
• Where do you stand regarding a move towards a model of increased end-to-end strategic partnering and intensification of collaboration models with partners across the industry? Is this increased model of collaboration something you are keen to see more of?
• What are the major challenges currently facing Big Pharma e.g., unpredictable supply chain, access to talent, investment into digital transformation?

Laia Crespo
Partner at Sanofi Ventures
Jan-Philipp Kruse
Senior Director, Open Innovation of Bayer AG
Laura Lane
VP at Eli Lilly & Co
Andrew McConaghie
Senior Writer at Citeline
Alistair Henry
Head of UK Research at UCB

12:00^PM - 12:30^PM

Keynote: Valuation for fundraising – what you need to know
Patrik Frei

Patrik Frei
CEO of Venture Valuation Inc.
Dr. Patrik Frei is founder and CEO of Venture Valuation AG, Switzerland, the company he started in 1999 based on a collaboration with the Novartis Venture Fund, which became his first client. Since then he has been involved in over 800 valuations around the globe for investors as well as Biotech, Pharma and Medtech companies. Venture Valuation runs two additional services/businesses: 1) Biotechgate, a global business development database. 2. HelloPartnering, a leading one2one partnering software including the Biotechgate Digital Partnering event (www.digitalpartnering.com). Patrik graduated from the Business University of St. Gallen in Finance and completed his Ph.D thesis at the Swiss Federal Institute of Technology, EPFL in Lausanne. Patrik has experience as a board member of public and private companies, published numerus articles and provides valuation workshops around the world.
More information about speaker

12:30^PM - 1:30^PM

Lunch & Networking

1:30^PM - 2:30^PM

Panel: Inspiring Women in Life Science
Jemma Contreras•Sheelagh Frame•Zahra Jawad•Carole Le Page•Debora Lucarelli

Kindly sponsored by BDO

This session has been designed to shine a light on some of the most inspiring women currently working in life sciences, with the moderator seeking to gain insight on the following questions:
• Was a career in life sciences always on the cards for you? What were the main drivers and inspirations that helped get you where you are today and did you face any challenges?
• What has been your proudest career moment or achievement to date?
• How dramatically have you seen the landscape shift for women in life science shift during your career so far?
• What are the factors that you believe make a successful team, and what has been the most powerful and impactful team that you’ve been part of during your career and why?
• How important is mentorship/sponsorship in ensuring new talent is brought through the ranks?
• What are your aspirations for both the impact that life sciences will have on society in the future, and your role within it? What are the key changes you would like to see within the industry?

Jemma Contreras
Executive Managing Director of Syneos Health
Sheelagh Frame
CSO at Ubiquigent Ltd
ZJ
Zahra Jawad
CEO of Creasallis
Carole Le Page
Tax Partner at BDO LLP
Debora Lucarelli
Chief Executive Officer at Enhanc3d Genomics

2:30^PM - 3:30^PM

Panel: The Evolving Role of the CRO
Kinga Bercsenyi, PhD•Thomas Mander•Frances Murphy•Lisa Page•Bharat Chudasama

CROs play a crucial role in the research, discovery, design and development of new products coming to market, with innovative R&D companies are looking to CROs to take the role of a strategic partner to not only manage the R&D process but also to share in the commitment to the success of their clinical program
This session gathers four outstanding research partner organisations to gain further insight into their service provision and unique expertise as well as insight on the following points:
• How have the needs of R&D companies regarding CRO’s changed over the last 5-10 years, and what are the driving factors of this change?
• What are the benefits of the new collaborative relationships?
• Can you share an insight into some recent success stories, and the extent of the collaborative support services you provide?
• How important are interpersonal relationship in ensuring both parties get the most out of the collaboration?
• How do you think the CRO/R&D company relationship will further evolve in the future?

Kinga Bercsenyi, PhD
VP of Business Development at Arctoris
Thomas Mander
CEO of Domainex
Frances Murphy
Regional Vice President, Clinical Business Solutions EU & APAC at Precision for Medicine
Lisa Page
Partner at Penningtons Manches Cooper LLP
Bharat Chudasama
Vice President, Head of Strategic Partnerships at Syneos Health

BioTrinity Panels, Interviews & Keynotes

We aim to deliver a well-rounded programme of presentations, discussions, and debate around a variety of subject matters prevalent in the life sciences industry today. We include a mix of scientific focused topics, which either address the latest innovation and research, or matters that are popular and much talked about in the current mainstream landscape, along with pertinent updates on the financing and investment landscapes, as well as regulatory and legislative updates from leading voices and decision makers.

We cover a lot of ground, and the range is broad, but we aim to support our delegates by delivering a programme that is digestible, useful, and thought-provoking.

Each R&D spotlight will include 5 x 10 minute company presentations from the most innovative companies working in; Oncology, Infectious Diseases, Microbiome, Rare Diseases, Medtech, Neuroscience, Inflammatory Disease and Cell and Gene Therapy. If you are a company seeking Series A investment or to partner assets, BioTrinity is for you! Contact events@obn.org.uk

Detailed below is an outline of all of the sessions, if you have any queries then please email events@obn.org.uk